 <h1>Omadacycline Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to omadacycline: oral tablet</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, omadacycline may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking omadacycline:</p><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>dizziness</li>
<li>fainting</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>fever</li>
<li>headache</li>
<li>hives, itching, skin rash</li>
<li>hoarseness</li>
<li>irritation</li>
<li>itching of the vagina or genitals</li>
<li>joint pain, stiffness, or swelling</li>
<li>nervousness</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>redness of the skin</li>
<li>sore mouth or tongue</li>
<li>stomach pain</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>thick, white vaginal discharge with mild or no odor</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>white patches in the mouth or on the tongue</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of omadacycline may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Nausea</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Belching</li>
<li>change or loss in taste</li>
<li>constipation</li>
<li>diarrhea</li>
<li>feeling of constant movement of self or surroundings</li>
<li>heartburn</li>
<li>increased sweating</li>
<li>indigestion</li>
<li>mouth or throat pain</li>
<li>sensation of spinning</li>
<li>stomach discomfort or upset</li>
<li>trouble sleeping</li>
<li>unusual drowsiness, dullness, or feeling of sluggishness</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to omadacycline: intravenous powder for injection, oral tablet</i></p><h3>General</h3><p>In the community-acquired bacterial pneumonia clinical trial, serious side effects were reported in 6% of patients treated with this drug and 6.7% of patients treated with moxifloxacin; therapy was discontinued due to any side effect in 5.5% of patients treated with this drug and 7% of patients treated with moxifloxacin.  In the pooled acute bacterial skin and skin structure infection trials, serious side effects were reported in 2.3% of patients treated with this drug and 1.9% of patients treated with comparator; therapy was discontinued due to side effects in 1.7% of patients treated with this drug and 1.5% of patients treated with comparator.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 30%), vomiting (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea, constipation</p>
<p><b>Frequency not reported</b>: Abdominal pain, dyspepsia, oral candidiasis, increased lipase<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site reactions (infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling, skin induration)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased ALT, increased AST, increased GGT</p>
<p><b>Frequency not reported</b>: Increased bilirubin<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p>
<p><b>Frequency not reported</b>: Tachycardia, atrial fibrillation<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p>
<p><b>Frequency not reported</b>: Dysgeusia, lethargy, vertigo<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Other</h3><p>In the community-acquired bacterial pneumonia clinical trial, mortality imbalance was observed with 8 deaths (2%) in patients treated with this drug compared to 4 deaths (1%) in patients treated with moxifloxacin.  All deaths (both treatment groups) occurred in patients older than 65 years; most patients had multiple comorbidities.  Causes of death varied and included worsening and/or complications of infection and underlying conditions.  The cause of the mortality imbalance has not been established.</p>
<p></p>
<p>In acute bacterial skin and skin structure infection trials, 1 death (0.1%) was reported in patients treated with this drug and 3 deaths (0.4%) were reported in patients treated with linezolid.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Death</p>
<p><b>Frequency not reported</b>: Fatigue, increased alkaline phosphatase, mortality imbalance<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Anemia, thrombocytosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Pruritus, erythema, hyperhidrosis, urticaria<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Oropharyngeal pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Increased creatine phosphokinase<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vulvovaginal mycotic infection<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Nuzyra (omadacycline)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about omadacycline</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: tetracyclines</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Omadacycline &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Omadacycline Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Nuzyra</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Pneumonia</li>
<li>Skin and Structure Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to omadacycline: intravenous powder for injection, oral tablet</i></p><h3>General</h3><p>In the community-acquired bacterial pneumonia clinical trial, serious side effects were reported in 6% of patients treated with this drug and 6.7% of patients treated with moxifloxacin; therapy was discontinued due to any side effect in 5.5% of patients treated with this drug and 7% of patients treated with moxifloxacin.  In the pooled acute bacterial skin and skin structure infection trials, serious side effects were reported in 2.3% of patients treated with this drug and 1.9% of patients treated with comparator; therapy was discontinued due to side effects in 1.7% of patients treated with this drug and 1.5% of patients treated with comparator.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 30%), vomiting (up to 17%)</p><p><b>Common</b> (1% to 10%): Diarrhea, constipation</p><p><b>Frequency not reported</b>: Abdominal pain, dyspepsia, oral candidiasis, increased lipase<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Infusion site reactions (infusion site extravasation, pain, erythema, swelling, inflammation, irritation, peripheral swelling, skin induration)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Increased ALT, increased AST, increased GGT</p><p><b>Frequency not reported</b>: Increased bilirubin<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension</p><p><b>Frequency not reported</b>: Tachycardia, atrial fibrillation<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache</p><p><b>Frequency not reported</b>: Dysgeusia, lethargy, vertigo<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia<sup>[Ref]</sup></p><h3>Other</h3><p>In the community-acquired bacterial pneumonia clinical trial, mortality imbalance was observed with 8 deaths (2%) in patients treated with this drug compared to 4 deaths (1%) in patients treated with moxifloxacin.  All deaths (both treatment groups) occurred in patients older than 65 years; most patients had multiple comorbidities.  Causes of death varied and included worsening and/or complications of infection and underlying conditions.  The cause of the mortality imbalance has not been established.</p><p></p><p>In acute bacterial skin and skin structure infection trials, 1 death (0.1%) was reported in patients treated with this drug and 3 deaths (0.4%) were reported in patients treated with linezolid.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Death</p><p><b>Frequency not reported</b>: Fatigue, increased alkaline phosphatase, mortality imbalance<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Anemia, thrombocytosis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Pruritus, erythema, hyperhidrosis, urticaria<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Oropharyngeal pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Increased creatine phosphokinase<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vulvovaginal mycotic infection<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Nuzyra (omadacycline)?</li>
</ul><h2>More about omadacycline</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: tetracyclines</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Omadacycline &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Omadacycline Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Pneumonia</li>
<li>Skin and Structure Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>